Kwara flags off free anti-HIV injection to strengthen prevention

Kwara State is taking a significant stride in its public health mission by rolling out a free, long-acting injectable anti-HIV medication. The introduction of Lenacapavir, administered twice a year, marks a pivotal advancement in HIV prevention, offering a crucial alternative to the daily oral regimens that many find challenging to adhere to. This initiative, launched at the Kwara State University Teaching Hospital, underscores the state's commitment to combating new infections and bolstering prevention strategies across its communities.

“

This marks not just the introduction of a new medical intervention, but a bold step forward in our collective fight against HIV.

The rollout is part of a broader national strategy spearheaded by the Federal Government, aiming to eradicate AIDS as a public health threat by 2030. Kwara State, alongside the Federal Capital Territory and seven other states, has been chosen for the initial phase of this ambitious program. Health Commissioner Dr. Amina El-Imam highlighted that despite progress in testing and treatment, significant gaps in prevention persist, particularly among key and vulnerable populations. She emphasized that Lenacapavir is a "bold step forward" in addressing this challenge, targeting barriers such as stigma and adherence issues that often hinder the effectiveness of daily medication.

“

Kwara State continues to bear a measurable burden of HIV. While we have made progress in scaling up testing and treatment services, gaps remain in prevention, particularly among key and vulnerable populations.

Commissioner El-Imam further elaborated that this new intervention aligns seamlessly with Kwara's comprehensive health strategy, which focuses on expanding access and enhancing service delivery at all levels. The state is actively strengthening community-based prevention programs and integrating HIV care into primary healthcare services. The introduction of Lenacapavir is expected to significantly amplify these efforts, ensuring that those most in need receive accessible and effective preventative care. The government's commitment to equitable access is further reinforced through close collaboration with development partners, implementing agencies, and community stakeholders, aiming to scale up awareness and ensure efficient service delivery statewide.

“

Lenacapavir is a long-acting injectable antiretroviral administered twice yearly. It addresses one of the most persistent challenges in HIV control; adherence to daily medication, while its mechanism of action targets the HIV capsid to prevent viral replication.